Since 1941, Chong Kun Dang Pharmaceutical Corp. (CKD) has managed to lead Korean pharmaceutical industry and maintained its status as one of the top Korean pharmaceutical companies. From the development of generic drug to innovative drug, CKD is actively investing towards R&D to strengthen our presence not only in the domestic pharmaceutical market but also in the global market.

Main Product is Telminuvo. CKD have developed Telmisartan based products for many years. Telminuvo is IMD(Incrementally modified drug with unique combination of “telmisartan and s-amlodipine”. Telminuvo is growing by more than double digits every year and is ranked fifth in the ARB combination market.

Website : https://www.ckdpharm.com/